Preoperative SCC-Ag as a predictive marker for the use of adjuvant chemotherapy in cervical squamous cell carcinoma with intermediate-risk factors

CURRENT STATUS: UNDER REVIEW

Hong-tao Guo
Lanzhou University

Xue-han Bi
Lanzhou University

Ting Lei
Lanzhou University

Xiao Lv
Lanzhou University

Guang Yao
Lanzhou University

Yao Chen
Lanzhou University

Chang Liu
The First Hospital of Lanzhou University

chliumd@163.com Corresponding Author

DOI:
10.21203/rs.2.20782/v2

SUBJECT AREAS
Cancer Biology  Oncology

KEYWORDS
cervical cancer; chemotherapy; radiotherapy; squamous cell carcinoma antigen
Abstract

Purpose: For cervical cancer patients whose tumors display a combination of intermediate risk factors, postoperative radiation with or without adjuvant chemotherapy is suggested for them. However, who should be administered with adjuvant chemotherapy is unknown. The current study was designed to explore the clinical value of squamous cell carcinoma antigen (SCC-Ag) in guiding the use of adjuvant chemotherapy in cervical cancer patients.

Materials and Methods: A retrospective study of 301 cervical cancer patients treated by surgery and adjuvant treatment from March 2006 to March 2016 was performed. All patients were divided into two groups according to receiving adjuvant chemotherapy or not. Overall survival (OS), disease-free survival (DFS) were compared between patients who did and did not receive adjuvant radiotherapy. Multivariate analysis was employed to detect clinical factors associated with disease-free survival, local recurrence-free survival and distant metastasis-free survival.

Results: For patients with high pre-treatment SCC-Ag level, DFS and OS in adjuvant chemo-radiotherapy group were higher than that in adjuvant radiotherapy group. Besides, the rates of distant metastasis were found lower in patients who did receive adjuvant chemotherapy than those who did not. For patients with low pre-treatment SCC-Ag level, the 5-year OS and DFS were similar between groups of adjuvant chemo-radiotherapy and adjuvant radiotherapy. Multivariable analysis indicated adjuvant chemotherapy was independent predictors of DFS and distant metastasis-free survival (DMFS) in patients with high SCC-Ag level.

Conclusion: SCC-Ag can serve as an indication for the administration of adjuvant chemotherapy in cervical cancer patients.

Introduction

As we know, cervical cancer is the one of the most common cancer in women worldwide.

[1] The standard treatment for early-stage cervical cancer is surgery. However, adjuvant
chemo-radiotherapy plays still an important role in the integrated therapy when some pathological findings are found after surgery. The common factors such as lymph node metastasis, parametrial involvement and positive surgical margin are known as “high-risk” factors and patients with any of these features are suggested to receive postoperative concurrent chemo-radiotherapy.[2] But, for patients whose tumors present with a combination of intermediate risk factors such as large size, deep stromal invasion, and lymphovascular involvement, postoperative pelvic radiation is suggested for them with no mandatory need of adjuvant chemotherapy.[3] Thus, the problem is that who should be given with adjuvant chemotherapy is still unknown for the patients with two intermediate-risk factors. Moreover, there is also no consensus reached by physicians on this topic, leading to over or less treatment for some patients with intermediate-risk factors.

Squamous cell carcinoma antigen (SCC-Ag), which is produced through squamous formation of cervical squamous epithelium, is a biomarker routinely used in clinical practice.[4] Approximately 28% to 88% of cervical squamous cell carcinomas were with abnormal level of SCC-Ag level, which is very meaningful in cervical cancer patients.[5] Many studies found that pre-treatment SCC-Ag level could predict disease progression after treatments. [6-12] Besides, SCC-Ag was also employed to evaluate the response to treatment.[13] However whether preoperative SCC-Ag can be a predictive marker for the use of adjuvant chemotherapy in cervical squamous cell carcinoma is still unknown. In our present study, we tried to identify the clinical value of SCC-Ag in the administration of adjuvant chemotherapy in early stage cervical cancer with intermediate-risk factors. Our findings indicated that there was no need to administer adjuvant chemotherapy to patients with low preoperative SCC-Ag level. While, it was beneficial for patients with high SCC-Ag level to receive adjuvant chemotherapy. We just presented a novel use of SCC-Ag to be a marker for the effectiveness of adjuvant chemotherapy in the clinical practice. It could be
one of the first articles on the use of preoperative SCC-Ag in guiding the administration of adjuvant chemotherapy in patients with cervical cancer since few researches have investigated the relationship between SCC-Ag level and the use of adjuvant chemotherapy in cervical cancer patients with intermediate-risk factors.

**Materials And Methods**

**Ethics Statement**

This research was approved by the First Hospital of Lanzhou University, and written informed consent was obtained from every patient included in the study.

**Patients and procedures**

We acquired our data from a database at First Hospital of Lanzhou University from March 2006 to March 2016. The selection criteria for the current study were as follows: (1) pathologically confirmed uterine cervical cancer with two intermediate-risk factors; (2) received surgery followed by adjuvant radiotherapy or adjuvant chemo-radiotherapy; (3) the function of liver and renal function is normal; (4) no concurrent cancer and (5)did not receive radiotherapy to the pelvis previously. Patients with any high-risk factors were excluded. After careful reviewing the patients’ information, 301 patients met the inclusion criteria and were analyzed in the present study.

**Clinical Evaluation**

We performed the clinical staging with the help of physical examination, computed tomography or magnetic resonance imaging, and chest radiography. Besides, complete blood count and liver function test were also performed. Pre-treatment SCC-Ag levels were measured within 2 weeks before surgery. As for the method to measure serum SCC-Ag levels, we adopted sandwich enzyme linked immunosorbent assay (ELISA) technique by using ELISA Kit. In brief, 4-5ml venous blood samples were collected form the patients and centrifuged. First, we prepared the ELISA plates which were coated with an antibody
specific to SCC-Ag. Then, the standards and the samples were added to the ELISA plate wells. After incubation for 90 mins, a horseradish peroxidase-conjugated polyclonal antibody specific for SCC-Ag was added to each well to "sandwich" the SCC-Ag. Then, the plate was incubated for 30 mins and washed with wash buffer to remove components which were uncombined. Next, the substrate solution was added to each well, followed by a short period of incubation for 15 mins. The wells which contained SCC-Ag would present a color change. Finally, sulfuric acid solution was used to stop the enzyme-substrate reaction and we measured the color change by the method of spectrophotometry. The SCC-Ag concentration in each sample was estimated from the standard curve established based on the concentration of standards. All the patients included in our study were with elevated pre-treatment SCC-Ag levels (Range 2.21-45.57 ng/ml). (In our hospital, the normal level of SCC in healthy individuals is less than 2.00 ng/ml). The median level of SCC-Ag for the whole group of patients was 6.09ng/ml. And we adopted the median level of SCC-Ag to divide all the patients into two groups: high squamous cell carcinoma level group (>6.09 ng/ml) and low squamous cell carcinoma level group (≤6.09 ng/ml). The tumor size of 4cm was used as a cutoff value to differentiate tumor size and as a predictor of oncologic outcome according to the previously published researches [14-15].

**Chemotherapy**

Part of the patients received adjuvant chemotherapy. The regimen usually contained 5-Fu (3-4g/m², civ96h) and cisplatin(70mg/m²) and it was given to the patients every 3 weeks. Besides, other regimen including paclitaxel plus cisplatin was also used. And the details of this regimen are as follows: paclitaxel 135 mg/m² and cisplatin 70 mg/m². The median cycles of adjuvant chemotherapy were 3(2-4). Usually, two cycles of adjuvant chemotherapy were concurrent with postoperative radiotherapy.
Radiotherapy

Patients were suggested to receive postoperative radiation. The prescribed dose for the whole pelvis was 45–50 Gy/23-25F. And it was performed for 5 days per week with a total treatment duration of 5-6 weeks. As for the details of radiotherapy, the clinical target volume (CTV) included the primary tumor bed, para-cervical tissue, supra-vaginal portion, common iliac lymph nodes, internal and external iliac lymph nodes, obturator lymph nodes, and sacral lymph nodes. The superior border of the CTV was the bottom of L4, and the inferior border was the lower margin of the obturator. The anterior border was the posterior margin of the bladder and the posterior border was the anterior margin of the sacrum.

Follow-up evaluation

The patients were followed up every 3 months for the first 2 years and every 6 months during the following 3 years. After 5 years, they were suggested to visit their physician annually. Routine evaluations include complete blood cell counts, SCC-Ag, biochemical routines and physical examinations. Chest radiography and computed tomography or magnetic resonance imaging of the abdomen and pelvis were performed every 6 months. Disease-free survival and overall survival were defined from the date of diagnosis to the date of recurrence or metastasis and to the date of death, respectively. And for surviving patients, they were defined to the date of the last follow-up.

Statistical analysis

The statistical analyses were done by using SPSS software, version 20.0. Categorical variables were analyzed using the chi-square test or Fisher’s exact test. Continuous variables were analyzed using the Student’s t test or the Mann-Whitney U test. The comparisons of disease-free survival and overall survival rates between different group were performed by using Kaplan-Meier method. Multivariate analysis of disease-free
survival, local recurrence-free survival and distant metastasis-free survival was analyzed using Cox proportional hazards regression. P < 0.05 was considered to be statistically significant.

Results

Clinical Characteristics

In all, we enrolled 301 cervical cancer patients who were with two intermediate risk factors. Among them, 156 patients received adjuvant chemo-radiotherapy, while the rest of 145 patients received adjuvant radiotherapy alone. Compared to patients who received adjuvant radiotherapy alone, those who received chemo-radiotherapy presented no difference in clinical tumor stage, tumor size, lympho-vascular involvement, deep stromal invasion and follow-up. However, patients who did receive adjuvant concurrent chemotherapy tend to be younger than those who did not (Table 1).

Survival Analysis for the whole group

During the follow up, for the whole group, there were 40 patients who died. The 5-year overall survival in the adjuvant chemo-radiotherapy and adjuvant radiotherapy groups were 90.29% and 81.29%, respectively (Figure 1, table 2). No significant difference was showed in overall survival between the two groups Fifty-six patients suffered recurrence, of them, local recurrence was found in 13 patients, distant metastasis was showed in 28 patients and 15 patients were with both local and distant recurrences. The common metastatic sites were liver, lung, bone and lymph nodes. Compared to patients who did not received adjuvant chemotherapy, those who did acquired better disease-free survival (86.11% vs 74.89%, p=0.004) ((Figure2, table 2).

Survival Analysis for Patients with high Squamous Cell Carcinoma level

For patients with high SCC-Ag level, there were 25 cases who died and there were 33 patients who developed recurrence. Nine patients were with local recurrence alone and 13
patients suffered from only distant metastasis. Additionally, 11 patients presented with both local and distant metastasis. Patients in the adjuvant chemo-radiotherapy group acquired better 5-year OS (90.72% vs 73.41%, p=0.015) and DFS (86.03% vs 69.40%, p=0.007) than those in the adjuvant radiotherapy group (Figure 3 and 4, table 3). We also analyze the recurrence pattern, with result showing that there was no difference in local recurrence between groups with radiotherapy and chem-radiotherapy. However, distant metastasis was significantly higher in the radiotherapy group than that in the chemo-radiotherapy group (p=0.002) (table 4).

**Survival Analysis for Patients with low Squamous Cell Carcinoma level**

For patients with low SCC-Ag level, 23 patients recurred with 15 patents dying of tumor recurrence. Four patients recurred only locally, 15 patients had only distant metastasis and 4 patients developed both local and distant recurrences. The 5-year OS in the adjuvant chemo-radiotherapy and adjuvant radiotherapy groups was 90.65% and 88.74%, respectively (Figs 5, Table 5). The 5-year DFS in these two groups was 86.62% and 79.63%, respectively (Figs 6, table 5). No significant differences were found in both OS (p=0.097) and DFS (p=0.253). Further analysis of recurrence pattern results just showed that there were no differences in both the local and distant failure between patients did and did not receive adjuvant chemotherapy (table 6).

**Clinical predictors for disease-free survival, local recurrence-free survival and distant metastasis-free survival for patients with high Squamous Cell Carcinoma level**

For patients with high SCC-Ag level, results showed that tumor size and adjuvant chemotherapy were independent predictors of DFS and DMFS. Besides, adjuvant chemotherapy was found to be the unique factor significantly associated with DMFS, indicating that patients who received adjuvant chemotherapy suffered less distant failure
Discussion

Our current study demonstrated that, for patients with intermediate-risk factors, those who received adjuvant chemotherapy acquired better DFS than those who did not, although no significant differences was found in OS. Based on the pre-treatment SCC-Ag level, we further performed subgroup analysis with results showing that adjuvant chemotherapy was clinically meaningful only in patients with elevated SCC-Ag level by improving both the DFS and OS. However, in patients with low SCC-Ag level, adjuvant concurrent chemotherapy seemed to contribute little in improving the survival in this subgroup. Additional multivariable analysis further confirmed that adjuvant concurrent chemotherapy was independent prognostic factor for DFS, local recurrence-free survival and DMFS in cervical cancer patients with elevated SCC-Ag level.

In the present study, we found that preoperative SCC-Ag could act as a predictive marker for the use of adjuvant chemotherapy in cervical squamous cell carcinoma with intermediate-risk factors. Besides, increased pretreatment SCC-Ag levels was also a strong predictor of poor survival in cervical cancer patients and it has been widely used to predict the tumor recurrence after treatment.[10,16-17] In the study of Huang, et al, 188 patients with squamous cell carcinoma of the uterine cervix were retrospectively analyzed, with results showing that both SCC-Ag levels≥40 ng/mL (p < 0.001) and SCC-Ag levels of 10-40 ng/mL (p < 0.001) were significant factors for para-aortic lymph node recurrence. And the corresponding 5-year para-aortic lymph node recurrence rates were 84.8%, and 27.5%, respectively, which just indicated that higher level of SCC-Ag caused higher rate of para-aortic lymph node recurrence.[6] In another study performed by Liu et al, one hundred ninety-seven cervical cancer patients who had received curative treatment with FIGO stage IB1 were included. Their data revealed that, among squamous
cell carcinoma histology, patients with an Hb level less than 12 g/dl and a SCC-Ag level more than 3 ng/ml had worse oncologic outcomes.[8] Besides, some studies showed that elevated levels of SCC-Ag were significantly associated with lymph node metastasis, which was a major risk factor of impaired survival in cervical cancer patients.[18] But, the reported cut-off values of SCC-Ag level in predicting lymph node metastasis differed among the studies.[19-21]

For patients with intermediate-risk factors who received adjuvant postoperative radiotherapy, the main treatment failure was distant metastasis.[22] This may be the possible reason of that adjuvant radiotherapy could only decrease local-regional recurrence, but failed to improve OS.[23] Adjuvant chemotherapy could decrease the rate of distant metastasis, thus the addition of chemotherapy to the treatment may be reasonable for cervical cancer patients after surgery. And it has been reported that adjuvant chemotherapy was effective in early stage cervical cancer with surgically confirmed intermediate risk factors.[24] However, few studies has directly compared the efficacy between adjuvant chemo-radiotherapy and adjuvant radiotherapy in cervical cancer with intermediate risk factors. We found that SCC-Ag can be used to guide the adjuvant concurrent chemotherapy. In details, for patients with high pre-treatment SCC-Ag level, adjuvant therapy should be administered to them due to the improvement in survival. while, in patients with low SCC-Ag level, adjuvant chemotherapy failed to improve the oncologic outcome. As we know, this new finding was the first to be reported and we suggested a novel clinical use of squamous cell carcinoma antigen. Besides, we also found that tumor size and deep stromal invasion were independent predictors of DFS and DMFS, which was in consistent with other study.[25] Our multivariate analysis showed that adjuvant chemotherapy was significantly associated with DMFS, indicating that patients who received adjuvant chemotherapy suffered less distant failure than those who
did not. Based on the related discussion above, the possible explanation for our new finding were as follows: 1. high pre-treatment SCC-Ag level predicted high rates of recurrence and adjuvant chemotherapy was effective in cervical cancer patients with intermediate-risk factors; 2. Due to the poor survival in patients with high SCC-Ag level, adjuvant chemotherapy could significantly improve the oncologic outcome. However, in patients with low SCC-Ag level, the survival improvement brought by adjuvant chemotherapy may be little and not clinically significant because of the relatively favorable oncologic outcome in these patients who undergone adjuvant radiotherapy alone.

Some limitations were with our study. First, the selection bias could not be avoided because of the retrospective design of our study. But we found that most of the clinical variables were balanced between patients who did and did not have an elevated squamous cell carcinoma level. Secondly, the sample size in our work is relatively small. One of the reasons was that we only selected the patients with intermediate-risk factors, not including those with high-risk or no-risk factors. Besides, we chose the median pre-treatment level of SCC-Ag to divide all the patients into two group, which was based on the method adopted in other studies. [26-27]

In conclusion, pre-treatment SCC-Ag can be a predictive marker for the use of adjuvant chemotherapy in cervical squamous cell carcinoma with intermediate-risk factors. However, further larger-scale cohort studies are still warranted to prove this finding.

Declarations

Ethics approval and consent to participate

This research was approved by the First Hospital of Lanzhou University, and written informed consent was obtained from every patient included in the study.

Consent for publication
Not applicable

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests
The authors have no potential conflicts of interest to disclose.

Funding
No funding.

Authors' contributions
GHT conceived the study and wrote the manuscript. BXH and LT participated in the clinical data collection. LX and YG modified the figures. CY performed the statistical analysis. LC and GHT supervised and helped study design and participated in its design and final approval of the version to be published. All authors read and approved the final manuscript.

Acknowledgements
None

References
1. Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends--an update. Cancer Epidemiol Biomarkers Prev. 2016; 25:16–27.

2. Peters WA 3rd, Liu PY, Barrett RJ 2nd, Stock RJ, Monk BJ, Berek JS. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000 Apr;18(8):1606-13.

3. Rotman M, Sedlis A, Piedmonte MR. A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features:
follow-up of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):169-76.

4. Maruo, T., Yoshida, S., Samoto, T., Tateiwa, Y., Peng, X., Takeuchi, S. et al. Factors regulating SCC antigen expression in squamous cell carcinoma of the uterine cervix. Tumour Biol. 1998; 19: 494-50.

5. Ohara, K., Tanaka, Y., Tsunoda, H., Nishida, M., Sugahara, S., and Itai, Y. Assessment of cervical cancer radioresponse by serum squamous cell carcinoma antigen and magnetic resonance imaging. Obstet. Gynecol. 2002; 100: 781–787.

6. Huang, E.Y., Huang, Y.J., Chanchien, C.C., Lin, H., Wang, C.J., Sun, L.M. et al. Pretreatment carcinoembryonic antigen level is a risk factor for para-aortic lymph node recurrence in addition to squamous cell carcinoma antigen following definitive concurrent chemoradiotherapy for squamous cell carcinoma of the uterine cervix. Radiat. Oncol. 2012; 7: 13

7. Reesink-Peters, N., van der Velden, J., Ten Hoor, K.A., Boezen, H.M., de Vries, E.G., Schilthuis, M.S. et al. Preoperative serum squamous cell carcinoma antigen levels in clinical decision making for patients with early-stage cervical cancer. J. Clin. Oncol. 2005; 23: 1455–1462.

8. Liu, S.C., Huang, E.Y., Hu, C.F., Ou, Y.C., ChangChien, C.C., Wang, C.J. et al. Pretreatment factors associated with recurrence for patients with Cervical Cancer International Federation of Gynecology and Obstetrics Stage IB1 Disease. Gynecol. Obstet. Investig. 2016; 81: 339–34.

9. Jeong, B.K., Huh, S.J., Choi, D.H., Park, W., Bae, D.S., and Kim, B.G. Prognostic value of different patterns of squamous cell carcinoma antigen level for the recurrent cervical cancer. Cancer Res. Treat. 2013; 45: 48-54.

10. Shimura, K.M., Yokoi, T., Sasano, T., Sawada, K., Hamasaki, T., and Kimura, T. Utility
of serum squamous cell carcinoma antigen levels at the time of recurrent cervical cancer diagnosis in determining the optimal treatment choice. J. Gynecol. Oncol. 2013; 24: 321-329.

11. Fu J, Wang W, Wang Y, Liu C, Wang P. The role of squamous cell carcinoma antigen (SCC Ag) in outcome prediction after concurrent chemoradiotherapy and treatment decisions for patients with cervical cancer. Radiat Oncol. 2019 Aug 15;14(1):146.

12. Choi KH, Lee SW, Yu M, Jeong S, Lee JW, Lee JH. Significance of elevated SCC-Ag level on tumor recurrence and patient survival in patients with squamous-cell carcinoma of uterine cervix following definitive chemoradiotherapy: a multi-institutional analysis. J Gynecol Oncol. 2019 Jan;30(1): e1.

13. Hashimoto, K., Yonemori, K., Katsumata, N., Hirakawa, A., Hirata, T., Yamamoto, H. et al. Use of squamous cell carcinoma antigen as a biomarker of chemotherapy response in patients with metastatic cervical carcinoma. Eur. J. Obstet. Gynecol. Reprod. Biol. 2011; 159: 394-398.

14. Jhawar S, Hathout L, Elshaikh MA, Beriwal S, Small W Jr, Mahmoud O. Adjuvant Chemoradiation Therapy for Cervical Cancer and Effect of Timing and Duration on Treatment Outcome. Int J Radiat Oncol Biol Phys. 2017 Aug 1;98(5):1132-1141.

15. Kim SW, Chun M, Ryu HS, Chang SJ, Kong TW, Oh YT, et al. Long-term results of early adjuvant concurrent chemoradiotherapy for high-risk, early stage uterine cervical cancer patients after radical hysterectomy. BMC Cancer. 2017 Apr 28;17(1):297.

16. Gadducci A, Tana R, Cosio S, Genazzani AR. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature. Crit Rev Oncol Hematol. 2008 Apr;66(1):10-20.

17. Salvatici M, Achilarre MT, Sandri MT, Boveri S, Vanna Z, Landoni F. Squamous cell...
carcinoma antigen (SCC-Ag) during follow-up of cervical cancer patients: Role in the early diagnosis of recurrence. Gynecol Oncol. 2016 Jul;142(1):115-119.

18. Sakuragi N. Up-to-date management of lymph node metastasis and the role of tailored lymphadenectomy in cervical cancer. Int J Clin Oncol. 2007; 12:165-175.

19. Takeshima N. The value of squamous cell carcinoma antigen as a predictor of nodal metastasis in cervical cancer. Gynecol Oncol. 1998; 68:263-266.

20. Lin H, ChangChien CC, Huang EY. The role of pretreatment squamous cell carcinoma antigen in predicting nodal metastasis in early stage cervical cancer. Acta Obstet Gynecol Scand. 2000; 79:140-144.

21. van de Lande J, Davelaar EM, von Mensdorff-Pouilly S, Water TJ, Berkhof J, van Baal WM, et al. SCC-Ag, lymph node metastases and sentinel node procedure in early stage squamous cell cervical cancer. Gynecol Oncol. 2009; 112:119-125.

22. Chang SJ, Kim WY, Yoo SC, Yoon JH, Chun M, Chang KH, et al. A validation study of new risk grouping criteria for postoperative treatment in stage IB cervical cancers without high-risk factors: rethinking the Gynecologic Oncology Group criteria. Eur J Obstet Gynecol Reprod Biol. 2009 Nov;147(1):91-6.

23. Rogers L, Siu SS, Luesley D, Bryant A, Dickinson HO. Radiotherapy and chemoradiation after surgery for early cervical cancer. Cochrane Database Syst Rev. 2012 May 16;(5):CD007583.

24. Lee KB, Lee JM, Ki KD, Lee SK, Park CY, Ha SY. Comparison of adjuvant chemotherapy and radiation in patients with intermediate risk factors after radical surgery in FIGO stage IB-IIA cervical cancer. Int J Gynecol Cancer. 2008 Sep-Oct;18(5):1027-31.

25. Ayhan A, Al RA, Baykal C, Demirtas E, Ayhan A, Yüce K. Prognostic factors in FIGO stage IB cervical cancer without lymph node metastasis and the role of adjuvant radiotherapy after radical hysterectomy. Int J Gynecology Cancer. 2004 Mar-
26. Ogino I, Nakayama H, Okamoto N, Kitamura T, Inoue T. The role of pretreatment squamous cell carcinoma antigen level in locally advanced squamous cell carcinoma of the uterine cervix treated by radiotherapy. Int J Gynecol Cancer. 2006; 16: 1094–1100.

27. Kotowicz B, Fuksiewicz M, Jonska-Gmyrek J, Bidzinski M, Kowalska M. The assessment of the prognostic value of tumor markers and cytokines as SCCAg, CYFRA 21.1, IL-6, VEGF and sTNF receptors in patients with squamous cell cervical cancer, particularly with early stage of the disease. Tumour Biol. 2016; 37: 1271–1278.

Tables

| Variable                  | Adjuvant chemo-radiotherapy (n = 156) | Adjuvant radiotherapy (n = 145) | p value |
|---------------------------|--------------------------------------|-------------------------------|---------|
| Age, year                 |                                      |                               | 0.046   |
| median                    | 60                                   | 63                            |         |
| Stage                     |                                      |                               | 0.752   |
| IA2                       | 4                                    | 5                             |         |
| IB1                       | 88                                   | 82                            |         |
| IB2                       | 11                                   | 13                            |         |
| IIA1                      | 36                                   | 35                            |         |
| IIA2                      | 17                                   | 10                            |         |
| LVSI                      |                                      |                               | 0.562   |
| yes                       | 66                                   | 67                            |         |
| no                        | 90                                   | 78                            |         |
| DSI                       |                                      |                               | 1.000   |
| yes                       | 132                                  | 122                           |         |
| no                        | 24                                   | 23                            |         |
| Tumor size                |                                      |                               | 0.526   |
| ≥ 4                       | 114                                  | 101                           |         |
| < 4                       | 42                                   | 44                            |         |
| Risk group                |                                      |                               | 0.787   |
| large Tumor + DSI         | 90                                   | 78                            |         |
| large Tumor + LVSI        | 24                                   | 23                            |         |
| DSI + LVSI                | 42                                   | 44                            |         |
| Follow up, months         |                                      |                               | 0.932   |
| median                    | 56.9                                 | 56.6                          |         |

Abbreviation: DSI, deep stromal invasion; LVSI, lymph-vascular space invasion; SCC, squamous cell carcinoma;

Table 1
Patient Demographics and Baseline Tumor Characteristics
| Group                        | Adjuvant chemo-radiotherapy (n = 156) | Adjuvant radiotherapy (n = 145) | \( p \) value |
|-----------------------------|--------------------------------------|--------------------------------|---------------|
|                             | 3-year  | 5-year  | 3-year  | 5-year  |               |
| OS                          | 96.15%  | 90.29%  | 91.02%  | 81.29%  | 0.060         |
| DFS                         | 91.59%  | 86.11%  | 80.67%  | 74.89%  | 0.004         |

Abbreviations: OS = overall survival; DFS = disease-free survival.
#: calculated by Kaplan-Meier method

Table 2
Survival for the Whole Group Patients

| Group                        | Adjuvant chemo-radiotherapy (n = 84) | Adjuvant radiotherapy (n = 67) | \( p \) value |
|-----------------------------|--------------------------------------|--------------------------------|---------------|
|                             | 3-year  | 5-year  | 3-year  | 5-year  |               |
| OS                          | 94.05%  | 90.72%  | 86.57%  | 73.41%  | 0.015         |
| DFS                         | 89.16%  | 86.03%  | 77.61%  | 69.40%  | 0.007         |

Abbreviations: OS = overall survival; DFS = disease-free survival.
#: calculated by Kaplan-Meier method

Table 3
Survival for the Patients with high SCC level

| Group                        | Adjuvant chemo-radiotherapy (n = 84) | Adjuvant radiotherapy (n = 67) | \( p \) value |
|-----------------------------|--------------------------------------|--------------------------------|---------------|
|                             | 3-year  | 5-year  | 3-year  | 5-year  |               |
| LR                          | 5(6.0%) | 7(8.3%)  | 8(11.9%)| 10(14.9%)| 0.069         |
| SM                          | 5(6.0%) | 6(7.1%)  | 11(16.4%)| 18(26.9%)| 0.002         |

Abbreviations: LR = local recurrence; SM = systemic metastases
#: calculated by Kaplan-Meier method

Table 4
Recurrence Patterns for Patients with high SCC level

| Group                        | Adjuvant chemo-radiotherapy (n = 72) | Adjuvant radiotherapy (n = 78) | \( p \) value |
|-----------------------------|--------------------------------------|--------------------------------|---------------|
|                             | 3-year  | 5-year  | 3-year  | 5-year  |               |
| OS                          | 98.61%  | 90.65%  | 94.84%  | 88.74%  | 0.791         |
| DFS                         | 94.36%  | 86.62%  | 83.27%  | 79.63%  | 0.146         |

Abbreviations: OS = overall survival; DFS = disease-free survival.
#: calculated by Kaplan-Meier method

Table 5
Survival for the Patients with low SCC level
Group | Adjuvant chemo-radiotherapy (n = 72) | Adjuvant Radiotherapy (n = 78) | p value
--- | --- | --- | ---
| | 3-year | 5-year | 3-year | 5-year |
LR | 1(1.4%) | 3(4.2%) | 2(2.6%) | 5(6.4%) | 0.612
SM | 3(4.2%) | 8(11.1%) | 10(12.8%) | 11(14.1%) | 0.515

Abbreviations: LR = local recurrence; SM = systemic metastases
#: calculated by Kaplan-Meier method

Table 6
Recurrence Patterns for Patients with low SCC level

| Variable | DFS | | LRFS | | DMFS | |
| --- | --- | --- | --- | --- | --- | --- |
| | HR (95%CI) | p value | HR (95%CI) | p value | HR (95%CI) | p value |
| Adjuvant chemotherapy | 0.456(0.217–0.957) | 0.038 | 0.538(0.207–1.401) | 0.204 | 0.282(0.111–0.721) | 0.008 |
| Yes vs no | | | | | | |
| Tumor size | 2.988(1.278–6.984) | 0.012 | 3.213(1.426–7.335) | 0.007 | 1.731(0.701–4.276) | 0.234 |
| ≥4 cm vs <4 cm | | | | | | |
| DSI | 2.083(0.988–4.391) | 0.054 | 2.886(1.012–8.235) | 0.048 | 1.410(0.603–3.296) | 0.428 |
| Yes vs no | | | | | | |
| LVSI | 0.645(0.319–1.302) | 0.221 | 0.610(0.241–1.541) | 0.296 | 0.658(0.288–1.501) | 0.319 |

Abbreviations: DFS, disease-free survival; LRFS, local recurrence-free survival; DMFS, distant metastasis-free survival; DSI, deep stromal invasion; LVSI, lymph-vascular space invasion; SCC, squamous cell carcinoma;

Table 7
Multivariate Analyses of DFS, LRFS, and DMFS for Patients with high SCC level

Figures
Overall survival for the whole group of patients. No significant difference was found in overall survival between patients who did and did not receive concurrent chemotherapy (p = 0.060).
Disease-free survival for the whole group of patients. Significant difference was found in disease-free survival between patients who did and did not receive concurrent chemotherapy ($p = 0.004$).
Overall survival for the subgroup of patients with high squamous cell carcinoma level. Significant difference was found in overall survival between patients who did and did not receive concurrent chemotherapy ($p = 0.015$).
Figure 4

Disease-free survival for the subgroup of patients with high squamous cell carcinoma level. Significant difference was found in disease-free survival between patients who did and did not receive concurrent chemotherapy ($p = 0.007$).
Overall survival for the subgroup of patients with low squamous cell carcinoma level. No significant difference was found in overall survival between patients who did and did not receive concurrent chemotherapy ($p = 0.791$).
Disease-free survival for the subgroup of patients with low squamous cell carcinoma level. No significant difference was found in disease-free survival between patients who did and did not receive concurrent chemotherapy ($p = 0.146$).